Payment overview · 2025
General Payments
$102.80
1 reported records · 1 companies
Healthcare provider profile · identity verified
Ellen P Carrington, DO
Allopathic & Osteopathic Physicians|Internal Medicine · PITTSBURGH, PA · NPI 1437579414
Verified facts
What the public records show
CMS Open Payments records show Ellen P Carrington, DO received $102.80 in general payments during 2025 across 1 reported records.
Amgen Inc. accounted for 100.0% of that reported general-payment amount.
The Open Payments records used for this analysis explicitly named 1 associated product.
These records do not establish that a payment influenced prescribing or medical care.
Separate record types
Research & Ownership
Research Payments (direct recipient): not present in the loaded data
Associated Research Funding (for example, named PI): not present in the loaded data
Ownership / Investment: not present in the loaded data
These categories are never added into the General Payments headline. Associated research funding must not be described as money the doctor personally received unless the source record supports that conclusion.
Who paid this doctor?
Companies in 2025 General Payments
| Reported company | Canonical company | Amount | Share | Records | Year |
|---|---|---|---|---|---|
| Amgen Inc. | Unresolved — no canonical attribution shown | $102.80 | 100.0% | 1 | 2025 |
What were the payments for?
Payment categories
| Category | Amount | Records |
|---|---|---|
| Food and Beverage | $102.80 | 1 |
A meal, consulting fee, royalty, and travel payment describe different kinds of reported relationships and should not be interpreted as equivalent.
Analysis 1 · Payment-linked products
Products named in Open Payments records
| Reported product | Type | Reported company | Related amount* | Records | Year |
|---|---|---|---|---|---|
| EVENITY Normalized: evenity |
Biological | Amgen Inc. | $102.80 | 1 | 2025 |
Source payment records
|
|||||
* Product-associated amounts are non-additive because one payment record may name more than one product.
These products were named on specific Open Payments records. A named product does not show that the payment influenced treatment or prescribing.
Public prescribing for products named in payments
No exact normalized or approved-alias overlap was found in the loaded Part D year. This does not mean the doctor never prescribed the product.
The presence of the same drug in both datasets does not show that a payment caused or influenced a prescription.
Analysis 2 · Same-company prescribing overlap
Drugs reported in other payments from the same company that also appear in Medicare Part D
This analysis is independent from products named on this doctor’s individual payment records. A row appears only when the exact Open Payments reporting entity paid this doctor, that same reporting entity reported the drug or biological on at least 10 loaded General Payment records involving at least 2 distinct recipient NPIs, and this doctor has the same non-generic brand in public Part D data. This does not mean the company owns or manufactures the drug.
No publishable same-company prescribing overlap was found in the loaded Part D year. This does not mean the doctor never prescribed a drug reported elsewhere by a paying company.
These facts do not show that a payment was for the drug, that the company owns or manufactures the drug, or that a payment caused or influenced prescribing.
Public Medicare Part D data
Provider-and-drug rows loaded for 2024
| Brand | Generic | Claims | Beneficiaries |
|---|---|---|---|
| Atorvastatin Calcium | Atorvastatin Calcium | 666 | 182 |
| Amlodipine Besylate | Amlodipine Besylate | 458 | 117 |
| Lisinopril | Lisinopril | 331 | 80 |
| Levothyroxine Sodium | Levothyroxine Sodium | 295 | 69 |
| Hydrochlorothiazide | Hydrochlorothiazide | 234 | 58 |
| Carvedilol | Carvedilol | 219 | 45 |
| Rosuvastatin Calcium | Rosuvastatin Calcium | 202 | 66 |
| Eliquis | Apixaban | 193 | 35 |
| Omeprazole | Omeprazole | 184 | 53 |
| Tamsulosin Hcl | Tamsulosin Hcl | 167 | 46 |
| Escitalopram Oxalate | Escitalopram Oxalate | 153 | 35 |
| Valsartan | Valsartan | 150 | 38 |
| Trazodone Hcl | Trazodone Hcl | 147 | 40 |
| Albuterol Sulfate Hfa | Albuterol Sulfate | 141 | 44 |
| Gabapentin | Gabapentin | 141 | 46 |
| Furosemide | Furosemide | 137 | 35 |
| Losartan Potassium | Losartan Potassium | 137 | 39 |
| Metoprolol Succinate | Metoprolol Succinate | 135 | 44 |
| Pantoprazole Sodium | Pantoprazole Sodium | 126 | 28 |
| Famotidine | Famotidine | 125 | 35 |
| Metformin Hcl | Metformin Hcl | 122 | 29 |
| Montelukast Sodium | Montelukast Sodium | 117 | 28 |
| Metoprolol Tartrate | Metoprolol Tartrate | 114 | 31 |
| Tramadol Hcl | Tramadol Hcl | 114 | 26 |
| Fluticasone Propionate | Fluticasone Propionate | 112 | 39 |
| Pravastatin Sodium | Pravastatin Sodium | 106 | 22 |
| Azelastine Hcl | Azelastine Hcl | 103 | 51 |
| Potassium Chloride | Potassium Chloride | 103 | 25 |
| Celecoxib | Celecoxib | 96 | 32 |
| Alprazolam | Alprazolam | 87 | 18 |
| Oxycodone Hcl | Oxycodone Hcl | 86 | 22 |
| Allopurinol | Allopurinol | 85 | 18 |
| Trelegy Ellipta | Fluticasone/Umeclidin/Vilanter | 83 | 17 |
| Metformin Hcl Er | Metformin Hcl | 81 | 31 |
| Olmesartan Medoxomil | Olmesartan Medoxomil | 80 | 21 |
| Simvastatin | Simvastatin | 80 | 24 |
| Lorazepam | Lorazepam | 79 | 27 |
| Sertraline Hcl | Sertraline Hcl | 78 | 24 |
| Spironolactone | Spironolactone | 71 | 15 |
| Citalopram Hbr | Citalopram Hydrobromide | 67 | 15 |
| Methocarbamol | Methocarbamol | 67 | 30 |
| Warfarin Sodium | Warfarin Sodium | 67 | 12 |
| Atenolol | Atenolol | 65 | 18 |
| Bupropion Xl | Bupropion Hcl | 64 | 14 |
| Ozempic | Semaglutide | 58 | 12 |
| Jardiance | Empagliflozin | 56 | 16 |
| Mounjaro | Tirzepatide | 56 | 11 |
| Repaglinide | Repaglinide | 54 | 11 |
| Triamcinolone Acetonide | Triamcinolone Acetonide | 53 | 37 |
| Duloxetine Hcl | Duloxetine Hcl | 52 | 20 |
| Breo Ellipta | Fluticasone/Vilanterol | 51 | suppressed |
| Nifedipine Er | Nifedipine | 51 | 15 |
| Fluoxetine Hcl | Fluoxetine Hcl | 49 | 13 |
| Tradjenta | Linagliptin | 49 | 12 |
| Meloxicam | Meloxicam | 48 | 19 |
| Mirtazapine | Mirtazapine | 47 | 11 |
| Prednisone | Prednisone | 47 | 31 |
| Ezetimibe | Ezetimibe | 46 | 16 |
| Ventolin Hfa | Albuterol Sulfate | 45 | 18 |
| Synthroid | Levothyroxine Sodium | 43 | 11 |
| Zolpidem Tartrate | Zolpidem Tartrate | 43 | 11 |
| Ibuprofen | Ibuprofen | 42 | 12 |
| Glipizide Er | Glipizide | 41 | suppressed |
| Lantus Solostar | Insulin Glargine,hum.Rec.Anlog | 41 | 12 |
| Finasteride | Finasteride | 38 | 11 |
| Methylprednisolone | Methylprednisolone | 37 | 31 |
| Hydrocodone-Acetaminophen | Hydrocodone/Acetaminophen | 35 | suppressed |
| Irbesartan | Irbesartan | 35 | suppressed |
| Ondansetron Hcl | Ondansetron Hcl | 34 | 17 |
| Cyclobenzaprine Hcl | Cyclobenzaprine Hcl | 33 | suppressed |
| Valsartan-Hydrochlorothiazide | Valsartan/Hydrochlorothiazide | 33 | suppressed |
| Diltiazem 24hr Er (Cd) | Diltiazem Hcl | 32 | suppressed |
| Hydralazine Hcl | Hydralazine Hcl | 32 | suppressed |
| Esomeprazole Magnesium | Esomeprazole Magnesium | 29 | 11 |
| Bupropion Hcl | Bupropion Hcl | 28 | 12 |
| Fluticasone-Salmeterol | Fluticasone Propion/Salmeterol | 28 | 12 |
| Bumetanide | Bumetanide | 27 | suppressed |
| Tizanidine Hcl | Tizanidine Hcl | 27 | suppressed |
| Baclofen | Baclofen | 26 | suppressed |
| Ciclopirox | Ciclopirox | 26 | 18 |
| Levetiracetam | Levetiracetam | 26 | suppressed |
| Meclizine Hcl | Meclizine Hcl | 26 | suppressed |
| Nano 2nd Gen Pen Needle | Pen Needle, Diabetic | 26 | 12 |
| Amitriptyline Hcl | Amitriptyline Hcl | 25 | suppressed |
| Clopidogrel | Clopidogrel Bisulfate | 25 | suppressed |
| Pregabalin | Pregabalin | 24 | suppressed |
| Verapamil Hcl | Verapamil Hcl | 24 | suppressed |
| Clotrimazole-Betamethasone | Clotrimazole/Betamethasone Dip | 23 | suppressed |
| Isosorbide Mononitrate Er | Isosorbide Mononitrate | 23 | suppressed |
| Sumatriptan Succinate | Sumatriptan Succinate | 23 | suppressed |
| Terazosin Hcl | Terazosin Hcl | 23 | suppressed |
| Diclofenac Sodium | Diclofenac Sodium | 22 | suppressed |
| Oxycodone-Acetaminophen | Oxycodone Hcl/Acetaminophen | 22 | suppressed |
| Anoro Ellipta | Umeclidinium Brm/Vilanterol Tr | 21 | suppressed |
| Doxazosin Mesylate | Doxazosin Mesylate | 21 | suppressed |
| Naproxen | Naproxen | 21 | suppressed |
| Oxybutynin Chloride | Oxybutynin Chloride | 21 | suppressed |
| Oxybutynin Chloride Er | Oxybutynin Chloride | 21 | suppressed |
| Triamterene-Hydrochlorothiazid | Triamterene/Hydrochlorothiazid | 21 | suppressed |
| Telmisartan | Telmisartan | 20 | suppressed |
| Tolterodine Tartrate | Tolterodine Tartrate | 20 | suppressed |
| Trulicity | Dulaglutide | 19 | suppressed |
| Entresto | Sacubitril/Valsartan | 18 | suppressed |
| Fenofibrate | Fenofibrate Nanocrystallized | 18 | suppressed |
| Xarelto | Rivaroxaban | 18 | suppressed |
| Azithromycin | Azithromycin | 17 | 14 |
| Buspirone Hcl | Buspirone Hcl | 17 | suppressed |
| Clonazepam | Clonazepam | 17 | suppressed |
| Bisoprolol Fumarate | Bisoprolol Fumarate | 16 | suppressed |
| Hydrocortisone | Hydrocortisone | 16 | suppressed |
| Propranolol Hcl | Propranolol Hcl | 16 | suppressed |
| Toujeo Max Solostar | Insulin Glargine,hum.Rec.Anlog | 16 | suppressed |
| Losartan-Hydrochlorothiazide | Losartan/Hydrochlorothiazide | 15 | suppressed |
| Paroxetine Hcl | Paroxetine Hcl | 15 | suppressed |
| Budesonide-Formoterol Fumarate | Budesonide/Formoterol Fumarate | 14 | suppressed |
| Lansoprazole | Lansoprazole | 14 | suppressed |
| Novolog Flexpen | Insulin Aspart | 14 | suppressed |
| Cefdinir | Cefdinir | 13 | 12 |
| Doxycycline Monohydrate | Doxycycline Monohydrate | 13 | suppressed |
| Enalapril Maleate | Enalapril Maleate | 13 | suppressed |
| Glipizide | Glipizide | 13 | suppressed |
| Incruse Ellipta | Umeclidinium Bromide | 13 | suppressed |
| Jantoven | Warfarin Sodium | 13 | suppressed |
| Lisinopril-Hydrochlorothiazide | Lisinopril/Hydrochlorothiazide | 13 | suppressed |
| Ondansetron Odt | Ondansetron | 13 | suppressed |
| Solifenacin Succinate | Solifenacin Succinate | 13 | suppressed |
| Spiriva Respimat | Tiotropium Bromide | 13 | suppressed |
| Venlafaxine Hcl Er | Venlafaxine Hcl | 13 | suppressed |
| Bethanechol Chloride | Bethanechol Chloride | 12 | suppressed |
| Bupropion Hcl Sr | Bupropion Hcl | 12 | suppressed |
| Colchicine | Colchicine | 12 | suppressed |
| Dextroamphetamine-Amphet Er | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Dextroamphetamine-Amphetamine | Dextroamphetamine/Amphetamine | 12 | suppressed |
| Diltiazem 24hr Er | Diltiazem Hcl | 12 | suppressed |
| Droplet Pen Needle | Pen Needle, Diabetic | 12 | suppressed |
| Fluconazole | Fluconazole | 12 | suppressed |
| Glimepiride | Glimepiride | 12 | suppressed |
| Methimazole | Methimazole | 12 | suppressed |
| Midodrine Hcl | Midodrine Hcl | 12 | suppressed |
| Myrbetriq | Mirabegron | 12 | suppressed |
| Alendronate Sodium | Alendronate Sodium | 11 | suppressed |
| Ciprofloxacin Hcl | Ciprofloxacin Hcl | 11 | suppressed |
| Indomethacin | Indomethacin | 11 | suppressed |
| Nitroglycerin | Nitroglycerin | 11 | suppressed |
Timeline
Payment and prescribing data by year
Open Payments and Medicare Part D may refer to different years. They are shown separately rather than aligned as if they describe the same period.
| Year | General Payments | Main payer | Explicit products | Company overlaps | Part D coverage |
|---|---|---|---|---|---|
| 2025 | $102.80 · 1 records | Amgen Inc. | EVENITY | — | — |
| 2024 | — | — | — | — | Complete |
Questions to ask
Questions you could discuss with your doctor
- Are there reasonable alternatives I should understand when we discuss treatment options?
- How should I interpret the industry-payment records shown here in the context of my care?
These are general questions generated from reviewed templates. They are not personalized medical advice.
Sources and limitations
How to read this page
- Payment and Medicare prescribing data can cover different years; every comparison shows both years explicitly.
- Part D does not represent a doctor’s entire practice; it excludes many patients and is subject to CMS public-release thresholds.
- Company–drug relationships must have an auditable source, a precise relationship type, and a valid evidence period. Unresolved mappings are not published.
- Generic drug claims are not attributed to a specific manufacturer without manufacturer-level evidence.
- When a source extract is incomplete, missing rows are never treated as proof of no payments or no prescriptions.
Loaded source releases
| Dataset | Year | Publication | Source |
|---|---|---|---|
| CMS Open Payments — General Payments | 2025 | 2026-06-30 | Original source |
| Medicare Part D Prescribers by Provider and Drug | 2024 | 2026-05-06 | Original source |
| NPPES Data Dissemination V2 | current / reference data | 2026-08-10 | Original source |
Full methodology · Questions & answers · Report a possible error